Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16721704rdf:typepubmed:Citationlld:pubmed
pubmed-article:16721704lifeskim:mentionsumls-concept:C1533685lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C0085631lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C0006012lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C1272936lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C1276996lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C0086466lld:lifeskim
pubmed-article:16721704lifeskim:mentionsumls-concept:C1272883lld:lifeskim
pubmed-article:16721704pubmed:issue3lld:pubmed
pubmed-article:16721704pubmed:dateCreated2006-5-24lld:pubmed
pubmed-article:16721704pubmed:abstractTextAgitation is relatively common among Borderline Personality Disorder (BPD) patients in Psychiatric Emergency Services (PES). New injectable atypical antipsychotics are indicated for treatment in agitated psychotic or maniac patients but not for agitated BDP patients. Twenty agitated BPD patients were treated with intramuscular atypical antipsychotics (olanzapine or ziprasidone). Results suggest intramuscular atypical antipsychotics may be effective, fast and safe for treating acute BPD patients.lld:pubmed
pubmed-article:16721704pubmed:languageenglld:pubmed
pubmed-article:16721704pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:citationSubsetIMlld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16721704pubmed:statusMEDLINElld:pubmed
pubmed-article:16721704pubmed:monthMaylld:pubmed
pubmed-article:16721704pubmed:issn0176-3679lld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:SolerJJlld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:AlvarezEElld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:PérezVVlld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:PascualJ CJClld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:MadreMMlld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:CampinsM JMJlld:pubmed
pubmed-article:16721704pubmed:authorpubmed-author:BarrachinaJJlld:pubmed
pubmed-article:16721704pubmed:issnTypePrintlld:pubmed
pubmed-article:16721704pubmed:volume39lld:pubmed
pubmed-article:16721704pubmed:ownerNLMlld:pubmed
pubmed-article:16721704pubmed:authorsCompleteYlld:pubmed
pubmed-article:16721704pubmed:pagination117-8lld:pubmed
pubmed-article:16721704pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:meshHeadingpubmed-meshheading:16721704...lld:pubmed
pubmed-article:16721704pubmed:year2006lld:pubmed
pubmed-article:16721704pubmed:articleTitleInjectable atypical antipsychotics for agitation in borderline personality disorder.lld:pubmed
pubmed-article:16721704pubmed:publicationTypeLetterlld:pubmed
pubmed-article:16721704pubmed:publicationTypeComparative Studylld:pubmed